尼卡地平在射血分数降低的成人高血压急症中的应用价值
本研究为单中心回顾性研究,在年急诊量超过10万的学术一级创伤中心开展,评估尼卡地平在射血分数降低的成人急性心衰合并高血压(AHF-H)中的有效性和安全性。共审查500份病历,38例符合纳入标准(年龄≥18岁、急诊就诊6小时内启动尼卡地平持续静脉输注、3个月内超声心动图射血分数≤40%)。中位射血分数35%(IQR 25-40),中位BNP 731 pg/nL(IQR 418-3277),中位基线心率90 bpm、SBP 193 mmHg;医生设定的中位SBP目标为160 mmHg,全部患者在18分钟内达标。仅1例(2.6%)出现低血压和心动过缓,该患者射血分数20%、已插管、因主动脉夹层同时使用艾司洛尔,不良事件发生于右美托咪定启动后30分钟。作者认为尼卡地平在该人群中安全有效,但研究为回顾性、样本量小(38例),需进一步研究。
要点
- 38例射血分数≤40%的AHF-H患者中,医生设定的中位SBP目标为160 mmHg,全部患者达标,中位达标时间18分钟。
- 中位基线SBP 193 mmHg、心率90 bpm,尼卡地平持续静脉输注后仅1例(2.6%)出现低血压(SBP<90 mmHg)和心动过缓(<60 bpm)。
- 唯一不良事件患者射血分数20%、已插管、因主动脉夹层合用艾司洛尔,不良事件发生于右美托咪定启动后30分钟。
- 作者认为尼卡地平在射血分数降低的AHF-H成人中安全有效,但为回顾性、非干预性研究,仅38例。
- 作者称这是迄今评估该人群尼卡地平的最大研究,需进一步研究。
适用人群与场景
- 年龄≥18岁、因急性心衰合并高血压(AHF-H)就诊于急诊、射血分数≤40%(研究访视前3个月内超声心动图)的成人。
- 纳入条件:急诊就诊6小时内启动尼卡地平持续静脉输注。
- 排除:孕妇和囚犯。
- 研究场景:学术一级创伤中心急诊科,年急诊量超过10万。
诊断标准与关键阈值
- 射血分数≤40%依据研究访视前3个月内超声心动图判定。
- 有效性终点为达到医生设定的血压目标范围,中位SBP目标为160 mmHg。
- 安全性终点:使用尼卡地平期间及停药后15分钟内出现心动过缓(<60 bpm)或低血压(SBP<90 mmHg)。
处置流程与药物剂量
- 尼卡地平持续静脉输注,于急诊就诊6小时内启动,目标为医生设定的SBP范围(本研究中位目标160 mmHg)。
- 使用期间及停药后15分钟内监测心动过缓(<60 bpm)和低血压(SBP<90 mmHg)。
红旗征与不能漏的情况
- 低血压(SBP<90 mmHg)或心动过缓(<60 bpm):研究中1例(2.6%)同时出现,该患者射血分数20%、已插管、因主动脉夹层合用艾司洛尔,不良事件发生于右美托咪定启动后30分钟。
研究设计与关键结果
- 回顾性研究,在学术一级创伤中心(年急诊量超过10万)开展;审查500份病历,38例符合纳入标准。
- 中位(IQR)射血分数35%(25-40),中位BNP 731 pg/nL(418-3277)。
- 中位基线心率90 bpm、SBP 193 mmHg;医生设定的中位SBP目标160 mmHg,全部患者达标,中位达标时间18分钟。
- 1例(2.6%)出现低血压和心动过缓,该患者射血分数20%、已插管、因主动脉夹层合用艾司洛尔,不良事件发生于右美托咪定启动后30分钟。
证据类型、等级与局限
- 证据类型:回顾性、非干预性研究。
- 作者称这是迄今评估该人群尼卡地平的最大研究,但样本量仅38例。
- 局限:原文报告为回顾性研究、样本量小(38例),作者指出需进一步研究。
对床旁实践的改变
- 作者认为,在射血分数≤40%的AHF-H成人中,尼卡地平静脉输注用于降压是安全有效的。
- 本研究中位SBP目标为160 mmHg,全部患者18分钟内达标,提示该目标在此人群中可行。
- 合用艾司洛尔及后续启动右美托咪定时需关注低血压和心动过缓,研究中唯一不良事件发生于此情境。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nicardipine is commonly used in the management of hypertensive crises, except those involving cardiac contractility defects despite its ability to reduce afterload and pulmonary congestion. Consequently, there is limited literature evaluating nicardipine's role for this indication. The purpose of this study was to evaluate the efficacy and safety of nicardipine in adults with reduced ejection fractions presenting with acute heart failure with hypertension (AHF-H).
METHODS: This was a retrospective study conducted at an academic Level 1 trauma center with an annual Emergency Department (ED) volume surpassing 100,000. The purpose of this study was to determine the efficacy and safety of nicardipine in adults with reduced ejection fractions presenting to the ED with AHF-H. Efficacy was determined by achievement of the physician prescribed blood pressure target range. The primary safety endpoints included the number of individuals who experienced bradycardia (< 60 beats per minute, bpm) or hypotension (systolic blood pressure, SBP, < 90 mmHg) while receiving nicardipine and for up to 15 min after its discontinuation. Patients were included if they were ≥ 18 years of age, received a continuous intravenous nicardipine infusion within six hours of presenting to the ED, and had an ejection fraction ≤ 40% per an echocardiogram obtained within three months of the study visit. Pregnant and incarcerated patients were excluded.
RESULTS: Of the 500 patient charts reviewed, 38 met inclusion criteria. The median (interquartile, IQR) ejection fraction and brain natriuretic peptide (BNP) were 35% (25-40) and 731 pg/nL (418-3277), respectively. The median baseline heart rate and SBP were 90 bpm and 193 mmHg, respectively. The median physician specified SBP goal was 160 mmHg and all patients met this endpoint in a median time of 18 min. One (2.6%) patient in the total population developed both hypotension and bradycardia. This patient had an ejection fraction of 20%, was intubated, and received nicardipine in addition to esmolol for an aortic dissection without experiencing an adverse event until 30 min after dexmedetomidine was initiated.
CONCLUSION: In this non-interventional study evaluating the use of nicardipine in patients with reduced ejection fractions presenting to the ED with AHF-H, nicardipine was found to be safe and effective. To our knowledge this is the largest study to date evaluating nicardipine in this patient population and positively contributes to the existing literature.
参考来源
- Ibarra F, Holzmann S, Shah S, et al. Utility of nicardipine in the management of hypertensive crises in adults with reduced ejection fractions. Am J Emerg Med. 2023. PMID: 37924731. doi:10.1016/j.ajem.2023.10.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。